Licofelone Inhibits Interleukin‐18‐Induced Pro‐Inflammatory Cytokine Release and Cellular Proliferation in Human Mesangial Cells
Authors:
- 11 April 2012
- journal article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 111 (3) , 166-172
Abstract
Licofelone, a novel dual anti‐inflammatory drug that inhibits 5‐lipoxygenase (5‐LOX) and cyclooxygenase (COX), has recently been defined to have therapeutic effects in osteoarthritis. Both 5‐LOX and COX play functional roles in the pathogenesis of glomerulonephritis in children as well. Interleukin‐18 is a pro‐inflammatory cytokine. It remains unclear whether licofelone can ameliorate inflammatory response of human mesangial cells (HMC) exposed to interleukin‐18. In this study, HMC were cultured and exposed to interleukin‐18 with or without pre‐treatment of licofelone. COX‐2 and 5‐LOX enzyme activities in mesangial cells were determined with chromometry or high‐performance liquid chromatography. Prostaglandin E2, cysteinyl leukotriene, monocyte chemotactic protein‐1 and interferon‐γ concentrations in culture medium were measured using an enzyme‐linked immunosorbent assay. Western blotting was employed to detect phosphorylated mitogen‐activated protein kinases ERK1/2, p38 and JNK1/2 in HMC. It was found that licofelone attenuated interleukin‐18‐induced COX‐2 enzyme activity in HMC and prostaglandin E2 release in a dose‐dependent manner. Similarly, licofelone inhibited interleukin‐18‐induced 5‐LOX enzyme activity and leukotriene release. Licofelone reduced interleukin‐18‐induced phosphorylation of p38 mitogen–activated protein kinase and suppressed monocyte chemotactic protein‐1 and interferon‐γ synthesis. Moreover, licofelone inhibited IL‐18‐induced proliferation of mesangial cells. We conclude that licofelone inhibits interleukin‐18‐induced pro‐inflammatory cytokine release and cellular proliferation in HMC, which may represent a really interesting therapeutic approach for glomerulonephritis in children.Keywords
This publication has 27 references indexed in Scilit:
- Distinct Roles for Basal and Induced COX-2 in Podocyte InjuryJournal of the American Society of Nephrology, 2009
- Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRIAnnals of the Rheumatic Diseases, 2009
- Effects of receptor-mediated endocytosis and tubular protein composition on volume retention in experimental glomerulonephritisAmerican Journal of Physiology-Renal Physiology, 2009
- Licofelone: The answer to unmet needs in osteoarthritis therapy?Current Rheumatology Reports, 2008
- Activity and potential role of licofelone in the management of osteoarthritisClinical Interventions in Aging, 2007
- Licofelone-A Novel Analgesic and Anti-Inflammatory AgentCurrent Topics in Medicinal Chemistry, 2007
- Licofelone, a Balanced Inhibitor of Cyclooxygenase and 5-Lipoxygenase, Reduces Inflammation in a Rabbit Model of AtherosclerosisThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Regulatory effects of inducible nitric oxide synthase on cyclooxygenase-2 and heme oxygenase-1 expression in experimental glomerulonephritisNephrology Dialysis Transplantation, 2005
- Combined Lipoxygenase/Cyclo-oxygenase Inhibition in the ElderlyDrugs & Aging, 2005
- Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritisRheumatology, 2004